GeneDx Holdings Corp. (WGS) saw its stock price surge 5.15% during intraday trading on Monday. The significant upward movement followed the release of the company's fourth-quarter and full-year 2025 financial results.

The genetic testing company reported quarterly adjusted earnings of $0.14 per share, surpassing the analyst consensus estimate of $0.11. Revenue for the quarter reached $121 million, also beating expectations and marking a 26.5% increase year-over-year. A key growth driver was a 32% year-over-year rise in revenue from exome and genome tests, with test volumes growing 34.3%.

Further bolstering investor confidence, the company reaffirmed its full-year 2026 revenue guidance of $540 million to $555 million, which is above the current analyst consensus. The guidance anticipates 33% to 35% growth in its core exome and genome test revenue. Analysts maintain a positive outlook on the stock, with a consensus "buy" rating and a median 12-month price target significantly above recent trading levels.